Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis

References

• National Psoriasis Foundation About psoriasis: statistics. Available from: http://www.psoriasis.org/netcommunity/learn_statisticslearn_statistics. (Accessed 20 May 2011).
   Google Scholar
• National Institute of Arthritis and Musculoskeletal and Skin Disease Questions and answers about psoriasis. Available from: http://www.niams.nih.gov/Health_Info/Psoriasis/default.asp#2. (Accessed 20 May 2011).
   Google Scholar
• Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139.
   PubMed Web of Science ®Google Scholar
• Woodcock J, Wong B, Walsh J, Simpson R, Rodway G, Downing-Hayes T, Prevalence of cardiovascular risk factors and obstructive sleep apnea in patients with psoriasis and psoriatic arthritis [abstract 128]. J Invest Dermatol. 2010;130:S22.
   Google Scholar
• Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704–708.
   PubMed Web of Science ®Google Scholar
• Kaur R, Qureshi A, Dominguez P, Kumar S. Lifestyle factors and comorbidities in individuals with psoriasis andmental illness: a descriptive study [abstract 1910]. J Am Acad Dermatol. 2010;62:AB69.
   Google Scholar
• de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144:33–36.
   PubMed Web of Science ®Google Scholar
• Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc. 2004;9:131–135.
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–284.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol. 2001;145:610–616.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407.
   PubMed Web of Science ®Google Scholar
• Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512–518.
   PubMed Web of Science ®Google Scholar
• de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Invest Dermatol Symp Proc. 2004;9:140–147.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999;141:698–702.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073–3080.
   PubMed Web of Science ®Google Scholar
• Lewis V, Finlay A. 10 Years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9:169–180.
   PubMed Web of Science ®Google Scholar
• Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1:53.
   PubMedGoogle Scholar
• Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003;4:131–139.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004;150:317–326.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology. 2003;206:307–315.
   PubMed Web of Science ®Google Scholar
• Jobanputra R, Bachmann M. The effect of skin diseases on quality of life in patients from different social and ethnic groups in Cape Town, South Africa. Int J Dermatol. 2000;39:826–831.
   PubMed Web of Science ®Google Scholar
• Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P. Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol. 2005;85:409–413.
   PubMedGoogle Scholar
• Mork C, Wahl A, Moum T. The Norwegian version of the Dermatology Life Quality Index: a study of validity and reliability in psoriatics. Acta Derm Venereol. 2002;82:347–351.
   PubMedGoogle Scholar
• Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
   PubMed Web of Science ®Google Scholar
• Eghlileb AM, Davies EE, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol. 2007;156:1245–1250.
   PubMed Web of Science ®Google Scholar
• Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80:430–434.
   PubMed Web of Science ®Google Scholar
• McKenna SP, Lebwohl M, Kahler KN. Development of the US PSORIQoL: a psoriasis-specific measure of quality of life. Int J Dermatol. 2005;44:462–469.
   PubMedGoogle Scholar
• Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics. 1996;10:644–653.
   PubMedGoogle Scholar
• Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154:1161–1168.
   PubMed Web of Science ®Google Scholar
• Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol. 2004;122:602–627.
   PubMed Web of Science ®Google Scholar
• Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;215:17–27.
   PubMed Web of Science ®Google Scholar
• Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol. 1998;38:938–944.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152:954–960.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159:704–710.
   PubMed Web of Science ®Google Scholar
• Kimball A, Chen L, Mulani P, Gupta S. Health-related quality of life and work productivity among psoriasis patients by disease severity [abstract 3389]. J Am Acad Dermatol. 2009;60:AB184.
   Google Scholar
• Krueger GG, Langley RG, Finlay AY, Griffiths CE, Wooley JM, Lalla D, Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153:1192–1199.
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63:457–465.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162:137–146.
   PubMed Web of Science ®Google Scholar
• Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31–38.
   PubMed Web of Science ®Google Scholar
• Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware WE Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol. 2004;3:27–38.
   PubMedGoogle Scholar
• Ortonne JP, Shear N, Shumack S, Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol. 2005;5:13.
   PubMedGoogle Scholar
• Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007;17:381–386.
   PubMed Web of Science ®Google Scholar
• Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009;219:239–249.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18:341–350.
   PubMed Web of Science ®Google Scholar
• Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25–31.
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H. Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59:40–49.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719–726.
   PubMed Web of Science ®Google Scholar
• Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158:549–557.
   PubMed Web of Science ®Google Scholar
• Kimel M, Bell J, Sexton C, Revicki D. HRQL outcomes for assessing effectiveness in clinical trials of biological agents for psoriasis: a systematic review. Adv Psoriasis Inflamm Skin Dis. 2009;1:7–14.
   Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatology. 1978;157:238–244.
   Google Scholar
• Muhr T. User's manual for ATLAS.ti 5.0, ATLAS.ti scientific software development. Berlin: Atlas.ti GmbH; 2004.
   Google Scholar
• Creswell JW. Qualitative inquiry and research design: choosing among five methods. Thousand Oaks, CA: Sage Publications; 1998.
   Google Scholar
• Leidy NK, Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008;26:363–370.
   PubMed Web of Science ®Google Scholar
• Willis G. Cognitive interviewing. Thousand Oaks, CA: Sage Publications; 2005.
   Google Scholar
• DeWalt DA, Rothrock N, Yount S, Stone AA. Evaluation of item candidates: the PROMIS qualitative item review. Med Care. 2007;45:S12–S21.
   PubMed Web of Science ®Google Scholar
• Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24:1075–1082.
   PubMed Web of Science ®Google Scholar
• Wasel N, Poulin Y, Andrew R, Chan D, Fraquelli E, Papp K. A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. J Cutan Med Surg. 2009;13:294–302.
   PubMed Web of Science ®Google Scholar
• Zimolag I, Reich A, Szepietowski J. Influence of psoriasis on the ability to work [abstract OP76]. Acta Derm Venereol. 2009;89:575–576.
   Google Scholar